

Bibliography - Articles and References of Interest in TRANSFUSION MEDICINE

I.	Indications for Transfusion	2
II.	Adverse Reactions Associated with Transfusion.....	4
III.	Transfusion Associated Infections.....	8
IV.	Clinical Transfusion problems	14
V.	Component Preparation	16
VI.	Stem Cell Transplantation	16
VII.	Cord Blood	20
VIII.	Specialized Collections	21
IX.	Therapeutic Exchange	22
X.	Alternative to Transfusion.....	28
XI.	Erythropoietin.....	30
XII.	Epsilon-aminocaproic acid/Tranexamic acid/Aprotinin	30
XIII.	Intraoperative Autotransfusion	30
XIV.	Isovolemic Hemodilution	32
XV.	Postoperative Autotransfusion	32
XVI.	Pathogen Inactivation.....	33
XVII.	Derivatives	35
XVIII.	Donor Reactions	37
XIX.	Issues Relevant to Transfusion Medicine.....	38
XVIII.	Symposium on Transplantation.....	44
XIX.	Rheopheresis	45
XX.	Miscellaneous	46

I. Indications for Transfusion

A) Red Cells

- 1) "Perioperative Red Cell Transfusion." National Institutes of Health, Consensus Development Conference Statement. June 27-29, 1988.
- 2) Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles SM, Poole G, Williamson LM; British Committee for Standards in Haematology, Blood Transfusion Task Force. "Guidelines for the clinical use of red cell transfusion." British Journal of Haematology. 2001, 113, pp. 24-31.
- 3) Murphy MF, Atterbury CLJ, Chapman JF, Lumley JS, McClelland DBL, et al. "The administration of blood and blood components and the management of transfused patients." Transfusion Medicine. 1999; Volume 9, pp. 227-239.
- 4) "Guidelines for the estimation of fetomaternal haemorrhage." Transfusion Medicine. 1999; Volume 9, pp. 87-92.
- 5) Canadian Paediatric Society (CPS). "Red blood cell transfusions in newborn infants: Revised guidelines." Paediatrics & Child Health. 2002; 7(8): pp. 553-558.
- 6) M. Garrioch, J. Sandbach, E. Pirie, A. Morrison, A. Todd and R. Green. "Reducing red cell transfusion by audit, education and a new guideline in a large teaching hospital." Transfusion Medicine. 2004;14:25.
- 7) "Transfusion Guidelines for Neonates and Older Children." British Journal of Haematology. 2004, 124: pp. 433-453.
- 8) Covin R, O'Brien M, Grunwald G, Brimhall B, Sethi G, Walczak S, Reiquam W, Rajagopalan C, Shroyer AL, "Factors Affecting Transfusion of Fresh Frozen Plasma, Platelets, and Red Blood Cells During Elective Coronary Artery Bypass Graft Surgery." Arch Pathol Lab Med 2003 Vol 127, April, pp. 415-423.
- 9) Strauss, RG. "Controversies in the Management of the Anemia of Prematurity Using Single-Donor Red Blood Cell Transfusions and/or Recombinant Human Erythropoietin." Transfusion Medicine Reviews. 2006, Vol 20:1, pp. 34-44.
- 10) Rock G, Poon A, Haddad S, Romans R, St. Louis P. "Nutricel as an Additive Solution for Neonatal Transfusion." Trans Sci. 1999:20, pp. 29-36.
- 11) Strauss RG. "Blood Banking Issues Pertaining to Neonatal Red Blood Cell Transfusions." Transfusion Science. 1999:21, pp. 7-19.

- 12) Roseff SD, Luban NLC, Manno CS. "Guidelines for Assessing Appropriateness of Pediatric Transfusion." Transfusion. 2002;42, pp. 1398-1413.
- 13) Corwin HL, Carson JL. "Blood Transfusion – When Is More Really Less?" NEJM. 2007;.23;16:1667-1669.
- 14) Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, et al. "Transfusion Strategies for Patients in Pediatric Intensive Care Units." NEJM. 2007;356;16:1609-1619.
- 15) Gould Halme D, Kessler DA. "FDA Regulation of Stem-Cell-Based Therapies." NEJM. 2006;355(16):1730-1735.
- 16) Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. "Guidelines on the management of massive blood loss." Br J Haematol. 2006;135:634-641.

B) Plasma

- 1) "Fresh Frozen Plasma: Indications and Risks." National Institutes of Health, Consensus Development Conference Statement. June 27-29, 1988.
- 2) Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guideline Development Task Force of the College of American Pathologists. "Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate and Platelets." JAMA. 1994, 271: pp. 777-781.
- 3) "Guidelines for the use of fresh frozen plasma." Transfusion Medicine. 1992, 2: pp. 57-63.
- 4) Triulzi, DJ. "The art of plasma transfusion therapy." Transfusion. 2006;46:1268-1270.

C) Cryoprecipitate

- 1) Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guideline Development Task Force of the College of American Pathologists. "Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate and Platelets." JAMA. 1994, 271: pp. 777-781.

D) Cryo Poor Plasma

- 1) Teruya J, Styler M, Verde S, Topolsky D, Crilley P. "Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation." J Clin Apheresis. 2001; 16(4), pp. 169-74. Review.
- 2) Zeigler ZR, Shaddock RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE; North American TTP Group. "Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)." J Clin Apheresis. 2001; 16(1), pp. 19-22.
- 3) Douglas P. Blackall, Lynne Uhl, and Steven L. Spitalnik, for the Transfusion Practices Committee. "Cryoprecipitate-reduced plasma: rationale for use and efficacy in the treatment of thrombotic thrombocytopenic purpura." Transfusion. Volume 41, June 2001.

E) Platelets

- 1) "Platelet Transfusion Therapy." National Institutes of Health, Consensus Development Conference Statement. October 6-8, 1986.
- 2) "Guidelines for the Use Of Platelet Transfusions." British Journal of Haematology. 2003; 122, pp. 10-23.
- 3) "Guidelines for Platelet Transfusion." Transfusion Medicine. 1992; 2, pp. 311-318.
- 4) Tinmonth AT, Freedman J. "Prophylactic Platelet Transfusions: Which Dose is the Best Dose? A Review of the Literature." Transfus Med Rev. 2003; 17, pp. 181-93.

II. Adverse Reactions Associated with Transfusion

A) General

- 1) Sazama K, et al. "Practice Parameter for the Recognition, Management, and Prevention of Adverse Consequences of Blood Transfusion." Arch Pathol Lab Med. 2000; 124, pp. 61-70.
- 2) Lee D. "Perception of Blood Transfusion Risks." Transfusion Medicine Reviews. 2006; 20, pp 141-148.

- 3) Newman B. "Iron depletion by whole-blood donation harms menstruating females: The current whole-blood-collection paradigm needs to be changed." Transfusion. 2006;46:1667-1681.
- 4) Stainsby D, Jones H, Asher D, Atterbury C, et al. "Serious Hazards of Transfusion: A Decade of Hemovigilance in the UK." Trans Med Rev. 2006;20(4):273-282.

B) Transfusion Related Acute Lung Injury

- 1) ‡ Webert KE, Blajchman MA. "Transfusion-related acute lung injury." Transfusion Medicine Reviews. 2003;17, pp. 252-262.
- 2) § Popovsky MA, Davenport RD. "Transfusion-related acute lung injury: femme fatale?" Transfusion. 2001;41, pp. 312-315 (editorial).
- 3) § Palfi M, Berg S, Ernerudh J, Berlin G. "A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous?" Transfusion. 2001;41, pp. 317-322.
- 4) Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. "Prevalence of HLA sensitization in female apheresis donors." Transfusion 1999;39, pp.103-106.
- 5) Christopher C. Silliman, Daniel R. Ambruso, and Lynn K. Boshkov. "Transfusion-related acute lung injury." Blood. 15 March, 2005, Volume 105, Number 6.
- 6) Kleinman S, Caulfield T, Chan P, et al. "Towards an understanding of transfusion-related acute lung injury: Statement of a consensus panel." Transfusion. 2004: 44, pp.1774-89
- 7) Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J and Blajchman MA. "Proceedings of a Consensus Conference: Towards an Understanding of TRALI." Trans Med Rev. 2005: 19, pp. 2-31
- 8) Toy P, Popovsky M, Abraha E, et al. "Transfusion-related acute lung injury: Definition and review." Crit Care Med. 2005;33:pp. 721-6
- 9) Bux J. "Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion." Vox Sang. 2005; 89:1-10.
- 10) Holness L, Knippen MA, Simmons L, and Lachenbruch PA. "Fatalities Caused by TRALI." Transfusion Medicine Reviews. Vol 18, No 3 (July), 2004: pp 184-188.
- 11) Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, et al. "Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors." Blood. 2003;101(2):454-462.
- 12) Kleinman S. "A perspective on transfusion-related acute lung injury two years after the Canadian Consensus Conference." Transfusion. 2006;46:1465-1468.

13) Triulzi DJ. "Transfusion-Related Acute Lung Injury: An Update." Hematology. 2006:497-501.

C) Febrile, Non-Hemolytic Reactions

- 1) Yazer MH, Podlosky L, Clarke G, Nahirniak SM. "The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions platelet concentrates and RBC." Transfusion. 2004 Jan;44(1):10-5.
- 2) Perrotta PL, Snyder EL. "Non-infectious complications of transfusion therapy." Blood Rev. 2001 Jun;15(2):69-83. Review.

D) Cytokine Mediated Reactions

- 1) Muller-Steinhardt M, Kirchner H, Kluter H. "Impact of storage at 22 degrees C and citrate anticoagulation on the cytokine secretion of mononuclear leukocytes." Vox Sang. 1998;75(1):12-7.
- 2) Snyder EL. "The role of cytokines and adhesive molecules in febrile non-hemolytic transfusion reactions." Immunol Invest. 1995 Jan-Feb;24 (1-2):333-9. Review.

E) Post Transfusion Purpura

- 1) Abramson N, Eisenberg PD, Aster RH. "Post-Transfusion Purpura: Immunologic Aspects and Therapy." NEJM. 1974;291:1163-6.
- 2) Welling KL, Taaning E, Lund BV, Rosenkvist J, Heslet L. "Post-transfusion purpura (PTP) and disseminated intravascular coagulation (DIC)." Eur J Haematol. 2003 Jul;71(1):68-71.
- 3) Janatpour K, Holland PV. "Noninfectious serious hazards of transfusion." Curr Hematol Rep. 2002 Nov;1(2):149-55. Review.

F) Delayed Hemolytic Transfusion Reactions

- 1) Solanki D, and McCurdy PR. "Delayed hemolytic transfusion reactions. An often-missed entity." JAMA. 1978 Feb 20;239(8):729-31.

- 2) Talano JA, Hillery CA, Gottschall JL, Baylerian DM, and Scott JP. "Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease." Pediatrics. 2003 Jun;111(6 Pt 1):e661-5.
- 3) Pineda AA, Vamvakas EC, Gorden LD, Winters JL, Moore SB. "Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions." Transfusion. 1999 Oct;39(10):1097-1103. Erratum in: Transfusion. 2000 Jul;40(7):891.

G) Transfusion Related Immunomodulation (TRIM)

- 1) Blajchman MA. "Transfusion immunomodulation or TRIM: what does it mean clinically?" Hematology. 2005; 10 Suppl 1:208-14
- 2) Vamvakas EC. "Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting." Transfus Med Rev. 2002 Oct;16(4):304-14.
- 3) Vamvakas EC. "WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials." Transfusion. 2003;43:963.
- 4) Blumberg N. "Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt." Transfusion. 2005;45:33S-40S.
- 5) Vamvakas EC. "Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt." Letter to Editor. Transfusion. 2006;46:492-494.

H) Transfusion associated graft vs. host disease and donor leukocyte

- 1) Lee T-H, Paglieroni T, Ohto H, Holland PV, Busch MP. "Survival of Donor Leukocyte Subpopulations in Immunocompetent Transfusion Recipients Frequent Long-Term Microchimerism in Severe Trauma Patients." Blood. 1999;93:3127-39.
- 2) Lee T-H, Paglieroni T, Utter G, Chafets D, Gosselin RC, Reed W, Owings JT, Holland PV, Busch MP. "High-Level Long-Term White Blood Cell Microchimerism after Transfusion of Leukoreduced Blood Components to Patients Resuscitated after Severe Traumatic Injury." Transfusion. 45:1280-90, 2005.

- 3) Kruskall MS, Lee T-H, Assmann SF, Laycock M, Kalish LA, Ledermann M, Busch MP, for the Viral Activation Transfusion Study. "Survival of Transfused Donor White Cells in HIV-Infected Recipients." Blood. 98:272-279, 2001.

III. Transfusion Associated Infections

A) General

- 1) Wang B, Schreiber GB, Glynn SA, Nass CC, Smith JW, Higgins MJ, Hutching ST, Wright DJ, McEntire RL, Murphy EL; Retrovirus Epidemiology Donor Study. "Prevalence of transfusion-transmissible viral infections in first-time US blood donors by donation site." Transfusion. 2003 Jun;43(6):705-12.
- 2) Goodnough LT, Shander A, Brecher ME. "Transfusion medicine: looking to the future." Lancet. 2003 Jan 11;361(9352):161-9. Review.
- 3) Busch MP, Kleinman SH, Nemo GJ. "Current and emerging infectious risks of blood transfusions." JAMA. 2003 Feb 26;289(8):959-62.
- 4) Jackson BR, Busch MP, Stramer SL, AuBuchon JP. "The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations." Transfusion. 2003 Jun;43(6):721-9.
- 5) Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP, for the NHLBI Nucleic Acid Test Study Group. "Detection of HIV-1 and HCV Infections Among Antibody-Negative Blood Donors by Nucleic Acid-Amplification Testing." N Engl J Med. 351:760-8, 2004.
- 6) Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, for the NHLBI-REDS NAT Study Group. "A New Strategy for Estimating Risks of Transfusion-Transmitted Viral Infections Based on Rates of Detection of Recently Infected Donors." Transfusion. 45:254-64, 2005.

B) Hepatitis B (HBV)

- 1) Ganem D, Prince AM: "Hepatitis B Virus Infection—Natural History and Clinical Consequences." NEJM. 2004;350:1118-29.

- 2) Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP, for the Retrovirus Epidemiology Donor Study. "Frequency of HBV DNA Detection in US Blood Donors Testing Positive for anti-HBc: Implications for Transfusion Transmission and Donor Screening." Transfusion. 43:696-704, 2003.
- 3) Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. "Comparative Sensitivity of HBV NATs and HBsAg Assays for Detection of Acute HBV Infection." Transfusion. 43:788-98, 2003.

C) HTLV

- 1) Manns A, Wilks RJ, Murphy EL, Haynes G, Figueroa JP, Barnett M, Hanchard B, Blattner WA. "A prospective study of transfusion transmission of HTLV-I and risk factors associated with seroconversion." Int J Cancer. 1992; 51:886-91.
- 2) Manns A, Murphy EL, Wilks R, Haynes G, Figueroa JP, Hanchard B, Barnett M, Drummond J, Waters D, Cerney M, Seals JR, Alexander SS, Lee H, Blattner WA. "Detection of early HTLV-I antibody patterns during seroconversion among transfusion recipients." Blood. 1991; 77:1-10.
- 3) Fernando A Proietti, Anna Barbara F Carneiro-Proietti, Bernadette C Catalan-Soares and Edward L Murphy. "Global epidemiology of HTLV-I infection and associated diseases." Oncogene. (2005) 24, 6058–6068.
- 4) Diana F. Roucoux and Edward L. Murphy. "The Epidemiology and Disease Outcomes of Human T-Lymphotropic Virus Type II." AIDS Reviews. 2004;6: 145-155.

D) Hepatitis C (HCV)

- 1) Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP; Transfusion-Transmitted Viruses Study; Retrovirus Epidemiology Donor Study. "HCV viral load in anti-HCV-reactive donors and infectivity for their recipients." Transfusion. 2003 Oct;43(10):1433-41.
- 2) Dore GJ, Freeman AJ, Law M, Kaldor JM. "Is severe liver disease a common outcome for people with chronic hepatitis C." J Gastroenterol Hepatol. 2002 Apr;17(4):423-30. Review.

- 3) Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ. "Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)." Hepatology. 2000 Mar;31(3):756-62
- 4) Busch MP. "Insights into the Epidemiology, Natural History and Pathogenesis of Hepatitis C Virus Infection from Studies of Infected Donors and Blood Product Recipients." Transfusion Clinique et Biologique. 8:200-206, 2001.
- 5) Glynn SA, Wright DJ, Kleinman SH, Hirschhorn D, Tu Y, Heldebrant C, Smith R Giachetti C, Gallarda J, Busch MP. "Dynamics of Viremia in Early Hepatitis C Virus Infection." Transfusion. 45:994-1002, 2005
- 6) Gasink LB, Blumberg EA, Localio AR, Desai SS, et al. "Hepatitis C Virus Seropositivity in Organ Donors and Survival in Heart Transplant Recipients." JAMA. 2006;296:1843-1850.
- 7) Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. "Viral and Host Factors in Early Hepatitis C Virus Infection." Hepatology. 42:86-92, 2005.
- 8) Busch MP, Glynn SA, Stramer S, Orland J, Murphy EL, Wright DJ, Kleinman S, NHLBI Retrovirus Epidemiology Donor Study (REDS) Group. "Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors." Transfusion. 46: 469-475, 2006

E) Human Immunodeficiency Virus (HIV-1/2)

- 1) Wang B, Schreiber GB, Glynn SA, Nass CC, Smith JW, Higgins MJ, Hutching ST, Wright DJ, McEntire RL, Murphy EL; Retrovirus Epidemiology Donor Study. "Prevalence of transfusion-transmissible viral infections in first-time US blood donors by donation site." Transfusion. 2003 Jun;43(6):705-12.
- 2) Goodnough LT, Shander A, Brecher ME. "Transfusion medicine: looking to the future." Lancet. 2003 Jan 11;361(9352):161-9. Review
- 3) Jackson BR, Busch MP, Stramer SL, AuBuchon JP. "The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations." Transfusion. 2003 Jun;43(6):721-9.
- 4) Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. "Dynamics of HIV Viremia and Antibody Seroconversion in Plasma Donors: Implications for Diagnosis and Staging of Primary HIV Infection." AIDS. 17:1871-9, 2003.

F) Hepatitis A

- 1) Diwan AH, Stubbs JR, Carnahan GE. "Transmission of hepatitis A via WBC-reduced RBCs and FFP from a single donation." Transfusion. 2003 Apr;43(4):536-40.

G) West Nile Virus (WNV)

- 1) Centers for Disease Control and Prevention (CDC). "Update: West Nile Virus Activity --- United States, January 1 – November 7, 2006." Morbidity and Mortality Weekly Report. Last reviewed 11/8/06.
- 2) Dodd RY. "Emerging infections, transfusion safety, and epidemiology." N Engl J Med. 2003 Sep 25;349(13):1205-6. Epub 2003 Sep 18.
- 3) Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. "West Nile virus infection: a new acute paralytic illness." Neurology. 2003 Jul 8;61(1):55-9. Review.
- 4) Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo PA, Kleinman SH. "Screening the Blood Supply for West Nile Virus RNA by Nucleic Acid Amplification Testing." N Engl J Med. 353:460-7, 2005.
- 5) Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L, for the NHLBI Retrovirus Epidemiology Study (REDS). "The 2003 West Nile Virus United States Epidemic: The America's Blood Centers Experience." Transfusion. 45:469-479, 2005.
- 6) Custer B, Tomasulo PA, Murphy EL, Caglioti S, Harpool D, McEvoy P, Busch MP. "Triggers for Switching from Minipool Testing by Nucleic Acid Technology to Individual-Donation Nucleic Acid Testing for West Nile Virus: Analysis of 2003 Data to Inform 2004 Decision Making." Transfusion. 44:1547-54, 2004.
- 7) Custer B, Busch MP, Marfin A, Petersen LR. "The Cost Effectiveness of Screening the U.S. Blood Supply for West Nile Virus." Annals Int Med. 2005; 143:486-92.
- 8) Pealer L. N., Marfin A. A., Petersen L. R., Lanciotti R. S., Page P. L., Stramer S. L., Stobierski M. G., Signs K., Newman B., Kapoor H., Goodman J. L., Chamberland M. E., the West Nile Virus Transmission Investigation Team. "Transmission of West Nile Virus through Blood Transfusion in the United States in 2002." N Engl J Med. 2003; 349:1236-1245, Sep 25, 2003.

H) Bacterial Contamination

- 1) Yomtovian R. "Bacterial Contamination of Blood: Lessons from the Past and Road Map for the Future." Transfusion. 2004;44:450-60.
- 2) Blajchman M, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. "Bacterial Detection of Platelets: Current Problems and Possible Resolutions." Transfusion Medicine Reviews. Vol 19, No 4 (October), 2005: pp 259-272
- 3) Silva MA, Gregory KR, Carr-Greer M.A, Holmberg JA, Kuehnert MJ, Brecher ME. "Summary of the AABB Interorganizational Task Force On Bacterial Contamination of Platelets: Fall 2004 impact survey." Transfusion. 2006;46:636-641.
- 4) Mohr H, Lambrecht B, Bayer A, Spengler H, Nicol S, Montag T, Müller TH. "Sterility Testing of Platelets Prepared from Deliberately Infected Blood Donations." Transfusion. 2006;46:486-491.
- 5) McDonald CP. "Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening." Transfusion Med. 2006;16:381-396.

I) Malaria

- 1) Busch MP, Kleinman SH, Nemo GJ. "Current and emerging infectious risks of blood transfusions." JAMA. 2003 Feb 26;289(8):959-62.
- 2) Dodd RY. "Transmission of parasites and bacteria by blood components." Vox Sang. 2000;78 Suppl 2:239-42. Review.

J) Chagas Disease

- 1) Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes-Espinosa M, Ron-Guerrero CS, Delgado-Mejia M, Pena-Munoz JG. "Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States." Transfusion. 2006;46, pp 298-304.
- 2) Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P. "The validity of serologic tests for *Trypanosoma cruzi* and the effectiveness of transfusional screening strategies in a hyperendemic region." Transfusion. 2005;45, pp 554-561.

K) Prions

- 1) Farrugia, J. W. Ironside, P. Giangrande. "Variant Creutzfeldt–Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty." Vox Sanguini. (2005) 89, 186–192
- 2) Schreiber GB, Sanchez AM, Garratty G, Nass CC, Tu Y, Busch MP, for the Retrovirus Epidemiology Donor Study. "Mammalian Brain Consumption by Blood Donors in the United States: Brains Today, Deferred Tomorrow?" Transfusion. 44:667-674, 2004.
- 3) Blajchman MA, Goldman M, Webert KE, Vamvakas EC, Hannon J, Delage G. "Proceedings of a Consensus Conference: The Screening of Blood Donors for Variant CJD." Transfusion Medicine Reviews. Vol 18, No 2 (April), 2004: pp 73-92

L) Cytomegalovirus

- 1) Drew WL, Tegtmeier G, Alter HJ, Laycock ME, Miner RC, Busch MP. "Frequency and Duration of Plasma CMV Viremia in Seroconverting Blood Donors and Recipients." Transfusion. 43:309-13, 2003.
- 2) Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Busch MP. "Cytomegalovirus DNA is Rarely Detected in Healthy Blood Donors Using Validated PCR Assays." Transfusion. 43:314-21, 2003.
- 3) Vamvakas, E. C. "Is White Blood Cell Reduction Equivalent to Antibody Screening in Preventing Transmission of Cytomegalovirus by Transfusion? A Review of the Literature and Meta-Analysis." Transfusion Medicine Reviews. Vol 19, No 3 July 2005 pp 181-199.

M) Human Herpes Virus 8 (HHV-8)

- 1) Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC, Forghani B, Glynn SA, Goedert JJ, Jenkins FJ, Lee T-H, Neipel F, Todd DS, Whitby D, Nemo GJ, Busch MP, for the Retrovirus Epidemiology Donor Study. "Multicenter Comparison of Serologic Assays and Estimation of Human herpesvirus 8 Seroprevalence among US Blood Donors." Transfusion. 43:1260-8, 2003.

N) Tick Borne disease

- 1) Leiby DA, Gill JE. "Transfusion-Transmitted Tick-Borne Infections:A Cornucopia of Threats." Transfusion Medicine Reviews. Vol 18, No 4 (October), 2004: pp 293-306.

IV. Clinical Transfusion problems

A) Warm Autoimmune and Cold Hemolytic Anemia

- 1) Dacie J. "The Immune Hemolytic Anemias: A Century of Exciting Progress in Understanding." Br J Haematol. 2001;114:770-85.
- 2) Gehrs C, Friedberg RC. "Autoimmune hemolytic anemia." Am J Haematol. 2002;69:258-71.
- 3) Petz LD. "Drug-Induced Hemolytic Anemia." Transfus Med Rev. 1993;7:242-54.
- 4) Salama A, Berghofer H, Mueller-Eckhardt C. "Red blood cell transfusion in warm-type autoimmune haemolytic anaemia." Lancet. 1992 Dec 19-26;340(8834-8835):1515-7.
- 5) Gertz MA. "Cold Hemolytic Syndrome." Hematology. 2006:19-23.
- 6) Hoffman PC. "Immune Hemolytic Anemia – Selected Topics." Hematology. 2006:13-18.

B) Platelet Refractory States

- 1) Yankee RA, Grumet FC, Rogentine GN: "Platelet Transfusion Therapy. The Selection of Compatible Platelet Donors for Refractory Patients by Lymphocyte HL-A Typing." NEJM. 1969;281:1208-12.
- 2) Kickler TS, Ness PM, Braine HG: "Platelet Crossmatching. A Direct Approach to the Selection of Platelet Transfusions for the Alloimmunized Thrombocytopenic Patient." Am J Clin Pathol. 1988;90:69-72.
- 3) The Trial to Reduce Alloimmunization to Platelets Study Group: "Leukocyte Reduction and Ultraviolet Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet Transfusions." NEJM. 1997;337:1861-9.
- 4) Delaflor-Weiss E, Mintz PD: "The Evaluation and Management of Platelet Refractoriness and Alloimmunization." Transfus Med Rev. 2000;14:180-96.

C) Alloimmune Neonatal Thrombocytopenia

- 1) Goldman M, Filion M, Prouix C, Chartrand P, Decary F. "Neonatal Alloimmune Thrombocytopenia." Transfus Med Rev. 1994;8:123-31.
- 2) Kaplan C. "Alloimmune Thrombocytopenia of the Fetus and the Newborn." Blood Reviews. 2002;16, pp 69-72.

D) Cold Agglutinins & Cryoglobulins

- 1) Zarkovic M, Kwaan HC. "Correction of hyperviscosity by apheresis." Semin Thromb Hemost. 2003 Oct; 29(5):535-42.
- 2) Trendelenburg M, Schifferli JA. "Cryoglobulins in chronic hepatitis C virus infection." Clin Exp Immunol. 2003 Aug; 133(2):153-5. Review.
- 3) McNicholl FP. "Clinical syndromes associated with cold agglutinins." Transfus Sci. 2000 Feb-Apr; 22(1-2):125-33. Review.
- 4) Hamblin T. "Management of cold agglutination syndrome." Transfus Sci. 2000 Feb-Apr; 22(1-2):121-4. Review.
- 5) Agarwal SK, Ghosh PK, Gupta D. "Cardiac surgery and cold-reactive proteins." Ann Thorac Surg. 1995 Oct; 60(4):1143-50. Review.
- 6) Della Rossa A, Tavoni A, Bombardieri S. "Hyperviscosity Syndrome in Cryoglobulinemia: Clinical Aspects and Therapeutic Considerations." Seminars in Thrombosis and Hemostasis. 2003;29,5, pp 473-477.
- 7) Tedeschi A, Barate C, Minola E, Morra E. "Cryoglobulinemia." Blood Reviews. 2007. doi:10.1016/j.blre.2006.12.002.

E) IgA Anaphylaxis

- 1) Sandler SG. "How I manage patients suspected of having had an IgA anaphylactic transfusion reaction." Transfusion. 2006;46:10-13.

V. Component Preparation

A) Leukocyte Reduction

- 1) Dzik S. "Prestorage leukocyte reduction of cellular blood components." Transfus Sci. 1994 Jun;15(2):131-9. Review.
- 2) Wortham ST, Ortolano GA, Wenz B. "A Brief History of Blood Filtration: Clot Screens, Microaggregate Removal, and Leukocyte Reduction." Transfusion Medicine Reviews. Vol 17, No 3 (July), 2003: pp 216-222
- 3) Ortolano G, Capetandes A, Wenz B. "A Review of Leukoreduction Therapy for Decreasing the Morbidity Associated with Cardiopulmonary Bypass and Acute Inflammatory Bowel Disease." Therapeutic Apheresis. 2002. 6(1): 110-129.
- 4) Schuetz AN, Hillyer KL, Roback JD, Hillyer CD. "Leukoreduction Filtration of Blood With Sickle Cell Trait." Transfusion Medicine Reviews. Vol 18, No 3 (July), 2004: pp 168-176
- 5) Fung MK, Moore K, Ridenour M, Mook W, Triulzi D. "Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery." Transfusion. 2006; 46: 386-391.

B) Low Volume Apheresis Platelets

- 1) Dumont LJ, Krailadsiri P, Seghatchian J, Taylor LA, Howell CA, Murphy MF. "Preparation and storage characteristics of white cell-reduced high-concentration platelet concentrates collected by anapheresis system for transfusions in utero." Transfusion. 2000 Jan; 40(1):91-100.

VI. Stem Cell Transplantation

A) Collection

- 1) Ford CD, Green W, Warenski S, Petersen FB. "Effect of prior chemotherapy on hematopoietic stem cell mobilization." Bone Marrow Transplant. 2004 May; 33(9):901-5.

- 2) Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley J, Szer J, Bradstock K, Buzyn A, Matcham J, Gratwohl A, Schmitz N. European Group for Blood and Marrow Transplantation (EBMT). "Differences between graft product and donor side effects following bone marrow or stem cell donation." Bone Marrow Transplant. 2003 Nov; 32(9):873-80.
- 3) "Immune Reconstitution Following Haematopoietic Stem Cell Transplantation." British Journal of Haematology. 2004: 124, 407–420.
- 4) Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P, and Szczepiorkowski ZM. "Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization." Transfusion 2006 Volume 46, April.
- 5) Deeg HJ, Friedman D, Bohr VA, Constine L, Jones IM, et al. "Transplantation and Aging." Biol of Bl and Marr Transpl. 2006;12:893-898.

B) Disease Indications and Results

- 1) Gasparetto C. "Stem cell transplantation for multiple myeloma." Cancer Control. 2004 Mar-Apr; 11(2):119-29.
- 2) Munshi NC, Barlogie B. "Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia." Semin Oncol. 2003 Apr; 30(2):282-5. Review.
- 3) Ginis I, Rao MS. "Toward cell replacement therapy: promises and caveats." Exp Neurol. 2003 Nov; 184(1):61-77. Review.
- 4) Linker CA. "Autologous stem cell transplantation for acute myeloid leukemia." Bone Marrow Transplant. 2003 May; 31(9):731-8. Review.
- 5) Gribben JG. "Autologous hematopoietic transplantation for low-grade lymphomas." Cytotherapy. 2002; 4(3):205-15. Review.
- 6) Silver RT. "Chronic myeloid leukemia." Hematol Oncol Clin North Am. 2003 Oct; 17(5):1159-73, vi-vii. Review.
- 7) Goldman JM, Melo JV. "Chronic myeloid leukemia—advances in biology and new approaches to treatment." N Engl J Med. 2003 Oct 9; 349(15):1451-64. Review.
- 8) Copelan EA. "Hematopoietic Stem-Cell Transplantation." NEJM. 2006;354,17, pp. 1813-1826.
- 9) Parimon T, Au DH, Martin PJ, Chien JW. "A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation." Ann Intern Med. 2006;144:407-414.
- 10) Daley GQ, Goodell MA, Evan Y, Snyder. "Realistic Prospects for Stem Cell Therapeutics." Hematology. 2003

- 11) Storb RF, Lucarelli G, McSweeney PA, Childs RW. "Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors." Hematology. 2003
- 12) Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, Devine S. "Stem Cell Mobilization." Hematology. 2003.
- 13) Walters MC. "Stem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy." Hematology. 2005: 66-73.
- 14) Cornelissen JJ, Löwenberg B. "Role of Allogeneic Stem Cell Transplantation in Current Treatment of Acute Myeloid Leukemia." Hematology. 2005:151-155.
- 15) Gribben, JG. "Salvage Therapy for CLL and the Role of Stem Cell Transplantation." Hematology. 2005: 292-296
- 16) Rice CM, Halfpenny CA, Scolding NJ. "Stem Cells for the Treatment of Neurological Disease." Transfusion Medicine. 2003, 13, 351–361
- 17) Porat Y, Porozov S, Belkin D, Shimone D, et al. "Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages." Br J Haematol. 2006:10/16/06 epub.
- 18) Milligan DW, Kochethu G, Dearden C, Estella Matutes E, MacConkey C, Catovsky D, on behalf of the UK National Cancer Research Institute (NCRI) Haematological Studies Group. "High Incidence of Myelodysplasia and Secondary Leukemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukemia." 2006 Blackwell Publishing Ltd, British Journal of Haematology. 133, 173–175.
- 19) Mato AR, Luger SM. "Autologous stem cell transplant in ALL: who should we be transplanting in first remission?" Bone Marrow Trans. 2006:37:989-995.
- 20) "Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence". Editorial. Bone Marrow Trans. 2006:38:1-4.
- 21) Anderson JE. Bone marrow transplantation for myelodysplasia." Blood Reviews. 2000:14:63-77.
- 22) Hari P, Pasquini MC, Vesole DH. "Cure of multiple myeloma – more hype, less reality." Bone Marrow Trans. 2006:37:1-18.
- 23) Grigg A, Hughes T. "Role of Allogeneic Stem Cell Transplantation for Adult Chronic Myeloid Leukemia in the Imatinib Era." Biol of Blood and Marr Trans. 2006:12:795-807.
- 24) Hough RE, Snowden JA, Wulfraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective." Br Jour Haem. 2004:128:432-459.
- 25) De Witte T, Oosterveld M, Muus P. "Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome." Blood Reviews. 2006:Article in Press.

- 26) Van Besien K. "The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma." Blood Reviews. 2006;20:235-244.
- 27) Dey BR, Spitzer TR. "Current status of haploidentical stem cell transplantation." Br Jour Haem. 2006;135:423-437.

C) Graft versus Host

- 1) Nollet KE, Holland PV. "Toward a coalition against transfusion-associated GVHD." Transfusion. 2003 Dec; 43(12):1655-7. Review.
- 2) Anderson K. "Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components." Transfusion. 2003 Dec; 43(12):1652-4. Review
- 3) Bhushan V, Collins RH Jr. "Chronic graft-vs-host disease." JAMA. 2003 Nov 19; 290(19):2599-603. Review.
- 4) Linden JV, Pisciotto PT. "Transfusion- Associated Graft-Versus-Host Disease and Blood Irradiation." Transfusion Medicine Reviews. 1992 April 1992; vi(2): 116-123.
- 5) Dall'Amico R, Messina C. "Extracorporeal Photochemotherapy for the Treatment of Graft-Versus-Host Disease." Therapeutic Apheresis. 2002 6(4): 296-304.
- 6) Komanduri KV, Couriel D, Champlin RE. "Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation: Evolving Concepts and Novel Therapies including Photopheresis." Biology of Blood and Marrow Transplantation. 2006 12:1-6

D) Graft versus Disease

- 1) Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. "Graft-versus-leukemia reactions in allogeneic chimeras." Blood. 2004 Feb 1; 103(3):767-76. Epub 2003 Sep 04. Review.
- 2) Slavin S. "Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation." Int J Hematol. 2003 Oct; 78(3):195-207. Review.

E) Manipulated Stem Cells (Reed)

- 1) Terando A, Chang AE. "Applications of gene transfer to cellular immunotherapy." Surg Oncol Clin N Am. 2002 Jul;11(3):621-43. Review.

VII. Cord Blood

- 1) Read EJ, Sullivan MT. "Cellular therapy services provided by blood centers and hospitals in the United States, 1999: an analysis from the Nationwide Blood Collection and Utilization Survey." Transfusion. 2004 Apr; 44(4):539-46.
- 2) Solves P, Perales A, Mirabet V, Blasco I, Blanquer A, Planelles D, Larrea L, Monleon J, Carbonell-Uberos F, Angeles Soler M. "Optimizing donor selection in a cord blood bank." Eur J Haematol. 2004 Feb; 72(2):107-12.
- 3) Zhang L, Yang R, Zhong CH. "Transplantation of umbilical cord blood derived endothelial progenitor cells: a promising method of therapeutic revascularization." Eur J Haematol. 2006: 76: 1-8.
- 4) Chao NJ, Emerson SG, Weinberg KI, "Stem Cell Transplantation (Cord Blood Transplants)." Hematology. 2004.
- 5) Tse W, LaughlinMJ. "Umbilical Cord Blood Transplantation: A New Alternative Option." Blood. 2005. 377-383.
- 6) Giralt S. "Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years?" Hematology. 2005: 364-369.
- 7) Spitzer TR. "Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor." Hematology. 2005: 390-395.
- 8) Wagner E, Duval M, Dalle J, Morin H, Bizier S, Champagne J, Champagne MA. "Assessment of cord blood unit characteristics on the day of transplant: comparison with data issued by cord blood banks." Transfusion. 2006:46:1190-1198.
- 9) Jansen M, Brand A, von Lindern JS, Scherjon S, Walther FJ. "Potential use of autologous umbilical cord blood red blood cells for early transfusion needs of premature infants." Transfusion. 2006:46:1049-1056.
- 10) Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. "Adult umbilical cord blood transplantation: a comprehensive review." Bone Marrow Trans. 2006:38:83-93.

VIII. Specialized Collections

A) Granulocyte Transfusions

- 1) van Burik JH, Weisdorf DJ. "Is it Time for a New Look at Granulocyte Transfusions" (Editorial). Transfusion. 2002; 42:1393-5.
- 2) Huebel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley SD, Chauncey TR, Bensinger WI, Boeckh M. "Granulocyte Transfusion Therapy for Infections in candidates and recipients of HPC Transplantation: A Comparative Analysis of feasibility and outcome for community donors versus Related Donors." Transfusion. 2002;42: 1414-21.
- 3) Strauss RG: "Granulocyte Transfusion Therapy." Hematology/Oncology Clinics of North America. 1994; 8:1159-66.
- 4) Bishton M, Chopra R. "The Role of Granulocyte Transfusions in Neutropenic Patients." British Journal of Haematology. 2004: 127, 501-508
- 5) Bashir S, Cardigan R, "Granulocyte concentrates: how can we assess their quality?." Transfusion Medicine. 2003: 13, 245-257
- 6) Moog R. "Donor Tolerance and Results of Stimulation With G-CSF Alone or in Combination with Dexamethasone for the Collection of Granulocytes." J Clin Apher. 2004:19:115-118.

B) Donor Lymphocyte Transfusions

- 1) Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. "Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression." Cancer Res. 2001 Dec 1; 61(23):8513-9.
- 2) Panoskaltsis N, Reid CDL, Knighty SC, "Immune Modulation with Dendritic Cells." Transfusion Medicine. 2004, 14, 81-96
- 3) Decker WK, Xing D, Shpall EJ, "Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease." Biology of Blood and Marrow Transplantation 2006 12:113-125
- 4) Arat M, Arslan O, Gurman G, Dalva K, Ozcan M, Ugur A, Ilhan O. "The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy." Transfus Apheresis Sci. 2004 Feb; 30(1):9-15.

- 5) Gilleece MH, Dazzi F. "Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia." Leuk Lymphoma. 2003 Jan; 44(1):23-8. Review.
- 6) Hester J. "A Clinical Role for Peripheral Blood Lymphocyte Infusions and Perspectives on Collection." Therapeutic Apheresis and Dialysis. 7(3):305–311.
- 7) Butcher BW, Collins Jr RH. "The graft-versus-lymphoma effect: clinical review and future opportunities." Bone Marrow Trans. 2005:36, pp. 1-17.

C) Automated Red Cell Collections

- 1) Harrison JF. "Automated red cell collection – quality and value." Trans Med. 2006:16:155-164.

IX. Therapeutic Exchange

A) Indications for Therapy - ASFA Categories

B) General Review Articles

- 1) Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton. "Therapeutic plasma exchange: an update from the Canadian Apheresis Group." Ann. Intern Med. 1999 Sep 21;131(6):453-62. PMID: 10498563.
- 2) Shehata N, Kouroukis C, Kelton JG. "A review of randomized controlled trials using therapeutic apheresis." Transfus Med Rev. 2002 Jul; 16(3):200-29. Review.
- 3) Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. "Complications of Therapeutic Plasma Exchange: Experience With 4857 Treatments." Therapeutic Apheresis and Dialysis. 9(5):391–395.
- 4) Siami GA, Siami FS. "Membrane Plasmapheresis in the United States: A Review Over the Last Twenty Years." Therapeutic Apheresis. 2001 5(4): 315-320.
- 5) Von Baeyer H, "Plasmapheresis in Immune Hematology: Review of Clinical Outcome Data with Respect to Evidence-Based Medicine and Clinical Experience" Ther Apher & Dial. 2003 Vol. 7, No. 1

- 6) Bosch T. "Therapeutic Apheresis—State of the Art in the Year 2005." Therapeutic Apheresis and Dialysis. 9(6):459–468.
- 7) Borberg H. "Quo vadis haemapheresis Current developments in haemapheresis." Trans Apher Sci. 2006:34:51-73.

C) Malaria

- 1) Kumar S, Kothari S, Karnad DR. "Predicting the reduction of parasitaemia following exchange transfusion in severe Plasmodium falciparum malaria: comparison of two mathematical formulae." Ann Trop Med Parasitol. 2003 Jul; 97(5):489-92.
- 2) Powell VI, Grima K. "Exchange transfusion for malaria and Babesia infection." Transfus Med Rev. 2002 Jul; 16(3):239-50. Review.
- 3) Riddle MS, Jackson JL, Sanders JW, Blazes DL. "Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis." Clin Infect Dis. 2002 May 1; 34(9):1192-8. Epub 2002 Apr 03.

D) Hyperviscosity

- 1) Zarkovic M, Kwaan HC. "Correction of hyperviscosity by apheresis." Semin Thromb Hemost. 2003 Oct; 29(5):535-42. PMID: 14631553
- 2) Simon JA, Lazo-Langner A, Duarte-Rojo A, Velazquez-Gonzalez A, Sanchez-Guerrero SA, Sanchez-Guerrero J. "Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjogren's syndrome." J Clin Apheresis. 2002; 17(1):44-6.
- 3) Drew MJ. "Plasmapheresis in the dysproteinemias." Ther Apher. 2002 Feb; 6(1):45-52. Review. PMID: 11886576
- 4) Siami GA, Siami FS. "Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis." Ther Apher. 1999 Feb; 3(1):8-19. Review.
- 5) Dominguez E, Sha E. "Apheresis in Cryoglobulinemia Complicating Hepatitis C and in Other Renal Diseases." Ther. Apheresis. 2002; 6(1) 69-76.

E) Therapeutic Leukoreduction

- 1) Strauss RA, Gloster ES, McCallister JA, Jimenez JF, Neuberg RW, Berry DH. "Acute cytoreduction techniques in the early treatment of hyperleukocytosis associated with childhood hematologic malignancies." Med Pediatr Oncol. 1985; 13(6):346-51. PMID: 3862936.
- 2) Baer MR, Stein RS, Dessypris EN. "Chronic lymphocytic leukemia with hyperleukocytosis. The hyperviscosity syndrome." Cancer. 1985 Dec 15; 56(12):2865-9.
- 3) Porcu P, Farag F, Marcucci G, Cataland SR, Kennedy MS, Bissell M. "Leukocytoreduction for Acute Leukemia." Therapeutic Apheresis. 2002; 6(1):15-23.

F) Guillain- Barre Syndrome

- 1) Kiproff DD, Hofmann JC. Division of Immunotherapy, California Pacific Medical Center and the Bay Area Mobile Apheresis Program, San Francisco, California, USA. dkiproffcai@aol.com. "Plasmapheresis in immunologically mediated polyneuropathies." Therap Apher Dial. 2003 Apr; 7(2):189-96. Review.
- 2) The Guillain-Barre' Syndrome Study Group. "The North American study of plasmapheresis in the Guillain-Barre syndrome." J Clin Apheresis. 1985; 2(4):315-20.
- 3) French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. "Plasma exchange in Guillain-Barre syndrome: one-year follow-up." Ann Neurol. 1992 Jul; 32(1):94-7..
- 4) Dutch Guillain-Barre study group. "Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome." J Neurol Neurosurg Psychiatry. 1998 Feb; 64(2):242-4.
- 5) "Plasma exchange versus intravenous immunoglobulin for Guillain-Barre syndrome." Ther Apher. 1997 May; 1(2):129-30.
- 6) "High dose intravenous immune globulins and plasma exchange in Guillain-Barre Syndrome." Ital J Neurol Sci. 1995 Oct; 16(7):487-92.
- 7) The Dutch Guillain-Barre Study Group. "Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study." Ann Neurol. 1994 Jun; 35(6):749-52. Erratum in: Ann Neurol 1994 Sep; 36(3):457.
- 8) Kincaid JC. "Apheresis in Treatment of the Inflammatory Demyelinating Peripheral Neuropathies." Ther Apher. 2002 6(1):53-56.

- 9) Dada MA, Kaplan AA. "Plasmapheresis Treatment in Guillain–Barré Syndrome: Potential Benefit over IVIg in Patients with Axonal Involvement." Ther Apher and Dialysis. 8(5):409–412

G) Myasthenia

- 1) "Plasmapheresis as preparatory method for thymectomy in myasthenia gravis". Arq Neuropsiquiatr. 1995 Sep; 53(3-A):411-5.
- 2) "Plasmapheresis in severe forms of myasthenia gravis." Artif Organs. 1998 Feb; 22(2):129-34.
- 3) "Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule." Acta Neurol Scand. 1999 Mar; 99(3):147-51.
- 4) Rosana Carandina-Maffeis, Anamarli Nucci, José F.C. Marques Jr, Eduardo G. Roveri , Beatriz H.M. Pfeilsticker, Solange G. Garibaldi, Leonardo de Deus-Silva Arq. "Plasmapheresis in the Treatment of Myasthenia Gravis. GRAVIS Retrospective study of 26 patients." Neuropsiquiatr. 2004;62(2):391-395.

H) Multiple Sclerosis

- 1) "Plasmapheresis in acute multiple sclerosis: rationale and results." J Clin Apheresis. 1991; 6(4):200-4. Review.
- 2) "Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros." Neurology. 1988 Jul; 38(7 Suppl 2):50-2.
- 3) "Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs." Neurology. 1985 Mar; 35(3):312-9.

I) Sickle Cell

- 1) Hilliard LM, Williams BF, Lounsbury AE, Howard TH. "Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients." Am J Hematol. 1998 Sep; 59(1):28-35.
- 2) Raff J, Dobson C, and Tsai H, "Transfusion of Polymerised Human Haemoglobin in a Patient with Severe Sickle-Cell Anaemia." The Lancet. Vol. 360, August 10, 2002, pp. 464-465.

- 3) Buck J, Casbard A, Llewelyn C, Johnson T, Davies S, Williamson L. "Preoperative transfusion in sickle cell disease: a survey of practice in England." Eur J Haematol. 2005; 75: 14–21.
- 4) Danielson CFM. "The Role of Red Blood Cell Exchange Transfusion in the Treatment and Prevention of Complications of Sickle Cell disease." Therapeutic Apheresis. 2002; 6(1): 24-31.
- 5) Swerdlow PS. "Red Cell Exchange in Sickle Cell Disease." Hematology. 2006:48-53.
- 6) Platt OS. "Prevention and Management of Stroke in Sickle Cell Anemia." Hematology. 2006:54-57.
- 7) Ballas SK, Marcolina MJ. "Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia." Transfusion. 2006; 46: 105-110.
- 8) Ould amar AK. "Red blood cells from donors with sickle cell trait: a safety issue for transfusion?" Trans Med. 2006:16:248-253.

J) TTP

- 1) Moake JL: "Thrombotic Microangiopathies." NEJM. 2002; 347:589-600.
- 2) McCarthy LJ, Dlott JS, Orazi A, Waxman D, Miraglia CC, Danielson CFM. "Thrombotic Thrombocytopenic Purpura: Yesterday, Today, Tomorrow." Therapeutic Apheresis and Dialysis. 8(2):80–86,
- 3) Von Baeyer H. "Plasmapheresis in Thrombotic Microangiopathy-Associated Syndromes: Review of Outcome Data Derived from Clinical Trials and Open Studies." Therapeutic Apheresis. 2002 6(4): 320-328.
- 4) Brecher ME. "How I approach a thrombotic thrombocytopenia purpura patient." Transfusion. 2006:46:687-689.
- 5) Kiss JE. "Randomized clinical trials in thrombotic thrombocytopenic purpura: where do we go from here?" Transfusion. 2006:46:1659-1662.
- 6) Sadler EJ. "Thrombotic Thrombocytopenic Purpura: A Moving Target." Hematology. 2006:415-420.
- 7) Teruya J, Styler M, Verde S, Topolsky D, Crilley P. "Questionable Efficacy of Plasma Exchange for Thrombotic Thrombocytopenic Purpura After Bone Marrow Transplantation." J Clin Apher. 2001:16:169-174
- 8) Zeigler ZR, Shaddock RK, Gryn JF, Rintels PB, George JN, et al. "Cryoprecipitate Poor Plasma Does Not Improve Early Response in Primary Adult Thrombotic Thrombocytopenic Purpura (TTP)." J Clin Apher. 2001:16:19-22.

- 9) George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. "Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders." J Clin Apher. 2006;21:49-56.

K) Renal Disease

- 1) Kaplan AA. "The Use of Apheresis in Immune Renal Disorders." Therapeutic Apheresis and Dialysis. 7(2):165–172.
- 2) Frascà GM, Soverini ML, Falaschini A, Tampieri E, Vangelista A, Stefoni S. "Plasma Exchange Treatment Improves Prognosis of Antineutrophil Cytoplasmic Antibody-associated Crescentic Glomerulonephritis: A Case-Control Study in 26 Patients from a Single Center." Therapeutic Apheresis and Dialysis. 7(6):540–546.

L) Therapeutic Plateletpheresis

- 1) Greist A. "The Role of blood Component Removal in Essential and Reactive Thrombocytosis." Therapeutic Apheresis. 6(1): 36-44.

M) Vasculitis

- 1) Guillevin L, Pagnoux C. "Indications of Plasma Exchanges for Systemic Vasculitides." Therapeutic Apheresis and Dialysis. 7(2):155–160.
- 2) Neuwelt CM. "The Role of Plasmapheresis in the Treatment of Severe Central Nervous System Neuropsychiatric Systemic Lupus Erythematosus." Therapeutic Apheresis and Dialysis. 7(2):173–182.

X. Alternative to Transfusion

A) Red Cell Substitutes (Oxygen Carrying Solutions)

- 1) Raff J, Dobson C, and Tsai H, "Transfusion of Polymerised Human Haemoglobin in a Patient with Severe Sickle-Cell Anaemia." The Lancet. Vol. 360, August 10, 2002, pp. 464-465.
- 2) Reid, T J. "Hb-Based Oxygen Carriers: Are We There Yet?" Transfusion. Vol. 43, February 2003, pp. 280-287.
- 3) Stowell C, Levin J, Spiess B, and Winslow R, "Progress in the Development of RBC Substitutes." Transfusion. Vol. 41, February 2001, pp. 287-299.
- 4) Tsai A. "Influence of cell-free Hb on local tissue perfusion and oxygenation in acute anemia after isovolemic hemodilution." Transfusion. 2001;41: pp. 1290-1298.
- 5) Mullon J, M.D., Giacoppe G, M.D., Clagett C, M.D., McCune D, M.D., and Dillard T, M.D., "Transfusions of Polymerized Bovine Hemoglobin in a Patient with Severe Autoimmune Hemolytic Anemia." NEJM. Vol. 342, No. 22, June 1, 2000, pp. 1638-1643.
- 6) Buehler PW, Alayash AI. "Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems." Transfusion. Volume 44, October 2004, 1516-1530.
- 7) Stowell CR. "What ever happened to blood substitutes?" Transfusion. Volume 44, October 2004: 1403-149\04.
- 8) Klein, HG. "The Prospects for Red-Cell Substitutes". NEJM. June 1, 2000: 342:1666-1668

B) Stealth Red Cells

- 1) Blackall D, Armstrong J, Meiselman H, and Fisher T, "Polyethylene Glycol-Coated Red Blood Cells Fail to Bind Glycophorin A-Specific Antibodies and are Impervious to Invasion by the Plasmodium Falciparum malarial parasite." Blood. Vol. 97, No. 2, January 2001, pp. 551-556.
- 2) Bradley A, Test S, Murad K, Mitsuyoshi J, and Scott M, "Interactions of IgM ABO Antibodies and Complement with Methoxy-PEG-Modified Human RBCs." Transfusion. Vol. 41, October 2001, pp. 1225-1233.
- 3) Murad K, Gosselin E, Eaton J, and Scott M, "Stealth Cells: Prevention of Major Histocompatibility Complex Class II-Mediated T-Cell Activation by Cell Surface Modification." Blood. Vol. 94, No. 6, September 15, 1999, pp. 2135-2141.

- 4) Murad K, Mahany K, Brugnara C, Kuypers F, Eaton J, and Scott M, "Structural and Functional Consequences of Antigenic Modulation of Red Blood Cells with Methoxypoly (Ethylene Glycol)." Blood. Vol. 93, No. 6, March 15, 1999, pp. 2121-2127.
- 5) Scott M, Bradley A, and Murad K, "Camouflaged Blood Cells: Low-Technology Bioengineering for Transfusion Medicine?" Transfusion Medical Reviews. Vol. 14, No. 1, January 2000, pp. 53-63.
- 6) Scott M, Murad K, Koumpouras F, Talbot M, and Eaton J, "Chemical Camouflage of Antigenic Determinants: Stealth Erythrocytes." Proc. Natl. Acad. Sci. USA. Vol. 94, July 1997, pp. 7566-7571.
- 7) Garratty G. "Progress in Modulating the RBC Membrane To Produce Transfusable Universal/Stealth Donor RBCs." Transfusion Medicine Reviews. Vol 18, No 4 (October), 2004: pp 245-256

C) Universal Red Cells

- 1) Garratty G, Telen M, and Petz L, "Red Cell Antigens as Functional Molecules and Obstacles to Transfusion." Hematology. pp. 445-462, American Society of Hematology, Washington, DC, 2002.
- 2) Goldstein J, Siviglia G, Hurst R, Lenny L, and Reich L, "Group B Erythrocytes Enzymatically Converted to Group O Survive Normally in A, B, and O Individuals." Science. Vol. 215, January 8, 1982, pp. 168-170.
- 3) Hoskins, Lansing C, and Boulding, Erwin T, "Changes in Immunologic Properties of Group A RBCs During Treatment with an A-Degrading exo-a-N-Acetyl-galactosaminidase." Transfusion. Vol. 41, July 2001, pp. 908-916.
- 4) Kruskall M, AuBuchon J, Anthony K, Herschel L, Pickard C, Biehl R, Horowitz M, Brambilla D, and Popovsky M, "Transfusion to Blood Group A and O Patients of Group B RBCs That Have Been Enzymatically Converted to Group O." Transfusion. Vol. 40, November 2000, pp. 1290-1298.
- 5) Lenny L, Hurst R, Zhu A, Goldstein J, and Galbraith R, "Multiple-unit and Second Transfusions of Red Cells Enzymatically Converted from Group B to Group O: Report on the End of Phase 1 Trials." Transfusion. Vol. 35, No. 11, 1995, pp. 899-902.
- 6) Lublin, Douglas M, M.D., PhD, "Universal RBCs." Transfusion. Vol. 40, November 2000, pp. 1285-1289.

XI. Erythropoietin

- 1) MacLaren R, Gasper J, Jung R, Vandivier RW. "Use of exogenous erythropoietin in critically ill patients." J Clin Pharm Ther. 2004 Jun;29(3):195-208.
- 2) Wilson A, Yu HT, Goodnough LT, Nissenson AR. "Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature." Am J Med. 2004 Apr 5;116 Suppl 7A:50S-57S. Review.
- 3) Goodnough LT. "The use of erythropoietin to increase red cell mass." Can J Anaesth. 2003 Jun-Jul;50(6 Suppl):S10-8. Review.
- 4) Knight K, Wade S, Balducci L. "Prevalence and outcomes of anemia in cancer: a systematic review of the literature." Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S. Review.
- 5) Bunn HF. "New Agents that Stimulate Erythropoiesis." Blood. 2006:10/10/06 epub.
- 6) Jelkmann W. "Erythropoietin after a century of research: younger than ever." Eu J Haem. 2007:78:183-205.

XII. Epsilon-aminocaproic acid/Tranexamic acid/Aprotinin

- 1) Manjunath G, Fozailoff A, Mitcheson D, Sarnak MJ. "Epsilon-aminocaproic acid and renal complications: case report and review of the literature." Clin Nephrol. 2002 Jul;58(1):63-7. Review.
- 2) Dunn CJ, Goa KL. "Tranexamic acid: a review of its use in surgery and other indications." Drugs. 1999 Jun;57(6):1005-32. Review.
- 3) Kozek-Langenecker SA, Mohammad SF, Masaki T, Green W, Kamerath C, Cheung AK. "The effects of aprotinin on platelets in vitro using whole blood flow cytometry." Anesth Analg. 2000 Jan;90(1):12-6

XIII. Intraoperative Autotransfusion

A) General

- 1) Waters J, MD, Potter P, MD, and Hobson D, "A Comparison of Red Cell Recovery Between Two Different Methods of Red Cell Washing." Anesth Analg. 2003; 97: pp. 1578-1581.
- 2) Waters J, MD, ShinJung Lee J, and Karafa M., "A Mathematical Model of Cell Salvage Efficiency." Anesth Analg. 2002, 95:1312-7, American Society of Anesthesiologists.

- 3) Waters J, MD, Lukauskiene E, MD, and Anderson M, MD, "Intraoperative Blood Salvage During Cesarean Delivery in a Patient with b Thalassemia Intermedia." Anesth Analg. 2003;97: pp. 1808-1809.
- 4) Waters J, MD, ShinJung J, MPH, et. al., "Preoperative Autologous Donation Versus Cell Salvage in the Avoidance of Allogeneic Transfusion in Patients Undergoing Radical Retropubic Prostatectomy." Anesth Analg. 2004; 98: pp. 537-542.
- 5) Giordano GF, Giordano DM, Wallace BA, Giordano KM, Prust RS, Sandler SG. "An analysis of 9,918 consecutive perioperative autotransfusions." Surg Gynecol Obstet. 1993 Feb;176(2):103-10.

B) Orthopedic Surgery

- 1) Mortelmans Y, MD, Vermaut G, MD, et.al., "Quality of Washed Salvaged Red Blood Cells During Total Hip Replacement: A Comparison Between the User of Heparin and Citrate as Anticoagulants." Anesth Analg. 1994;79: pp. 357-363.
- 2) Ramirez G, Romero A, Garcia-Vallejo J, and Munoz M, "Detection and Removal of Fat Particles from Postoperative Salvaged Blood in Orthopedic Surgery [Letters to the Editor]." Transfusion. Vol. 42, January 2002, pp. 66-75.
- 3) Munoz M, MD, PhD, Romero A, BSc, Campos A, MD, and Ramirez G, MD, PhD, "Detection of Fat Particles in Postoperative Salvaged Blood in Orthopedic Surgery [Letters to the Editor]." Transfusion. Vol. 44, April 2004, pp. 620-622.

C) Complications

- 1) Feigal David, Jr, MD, MPH, "FDA Public Health Notification: Paralysis from Absorbable Hemostatic Agent," April 2, 2004, Food and Drug Administration, Rockville, MD.
- 2) American Society of Anesthesiologists. "Autologous Blood Harmful for the Recipient? The Results of a Pilot Study." Anesth Analg. 2001, 93:566-72.
- 3) Tylman M, Bengtson P, Bengtsson A, "Activation of the Complement System by Different Autologous Transfusion Devices: An In Vitro Study." Transfusion. Vol. 43, March 2003, pp. 395-399.

D) Leukodepletion

- 1) Cross, MH, "Cell Salvage and Leukodepletion." Perfusion. 2001: 16(suppl): pp. 61-66.
- 2) Innerhofer P, MD, Wiedermann F, MD, et. al., "Are Leukocytes in Salvaged Washed Autologous Blood Harmful for the Recipient? The Results of a Pilot Study." Anesth Analg. 2001, 93:566-72, American Society of Anesthesiologists.
- 3) Waters J, MD, Tuohy M, MD, Hobson D, and Procop G, MD, "Bacterial Reduction by Cell Salvage Washing and Leukocyte Depletion Filtration." Anesthesiology. Vol.99, No. 3, September 2003, pp. 652-655, American Society of Anesthesiologists, Inc.

XIV. Isovolemic Hemodilution

- 1) "Guidelines for autologous transfusion. Peri-operative haemodilution and cell salvage." British Journal of Anaesthesia. 1997; 78, 768-771.
- 2) Bennett J, Haynes S, Torella F, Grainger H, McCollum C. "Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial." Transfusion. 2006;46:1097-1103.
- 3) Shander A, Perelman S. "The long and winding road of acute normovolemic hemodilution." Transfusion. 2006;46:1075-1079.

XV. Postoperative Autotransfusion

- 1) Giordano GF, Giordano DM, Wallace BA, Giordano KM, Prust RS, Sandler SG. "An analysis of 9,918 consecutive perioperative autotransfusions." Surg Gynecol Obstet. 1993 Feb;176(2):103-10.

XVI. Pathogen Inactivation

A) General

- 1) Kreil TR, Berting A, Kistner O, Kindermann J. "West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data." Transfusion. 2003 Aug; 43(8):1023-8.
- 2) Corash L. "Pathogen reduction technology: methods, status of clinical trials, and future prospects." Curr Hematol Rep. 2003 Nov; 2(6):495-502. Review.
- 3) Corash L. "Inactivation of Infectious Pathogens in Labile Blood Components: Meeting the Challenge." Transfus Clin Biol. 2001 ; 8 : 138-45
- 4) Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin I, Stramer S. "Protecting the Blood Supply From Emerging Pathogens: The Role of Pathogen Inactivation." Transfusion Medicine Reviews. Vol 19, No 2 (April), 2005: pp 110-126
- 5) Zavizion B, Serebryanik D, Serebryanik I, Chapman J, Purmal A. "Prevention of Yersenia Enterocolitis Pseudomonus flouescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process." Transfusion. 2003, 43:135-142
- 6) Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzler P, Conlan MG. "Pathogen Inactivation of Platelets with a Photochemical Treatment with Amotosolin HCL and Ultraviolet Light: Process used in the SPRINT Trial." Transfusion 2006 April Vol 46.
- 7) Burdick MD, Pifat DY, Petteway Jr SR, Cai K. "Clearance of Prions During Plasma Protein Manufacture." Trans Med Reviews. 2006;20,1, pp. 57-62.
- 8) Seghatchian J, deSousa G. "Pathogen-reduction systems for blood components: The current position and future trends." Trans and Apher Sci. 2006;35:189-196.

B) Psoralins

- 1) Corash L, Lin L. "Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease." Bone Marrow Transplant. 2004 Jan; 33(1):1-7.

- 2) Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U. "Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States." Clin Ther. 2003 Sep; 25(9):2464-86.
- 3) Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K. "Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV." Antimicrob Agents Chemother. 2003 Feb; 47(2):475-9.
- 4) Corash L. "Inactivation of infectious pathogens in labile blood components: meeting the challenge." Transfus Clin Biol. 2001 Jun;8(3): 138-45. Review.
- 5) Corash L. "Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates." Vox Sang. 2000; 78 Suppl 2:205-10. Review.

C) Inactine

- 1) Chapman J. "Progress in improving the pathogen safety of red cell concentrates." Vox Sang. 2000; 78 Suppl 2:203-4. Review.
- 2) Zavizion B, Pereira M, De Melo Jorge M, Serebryanik D, Mather TN, Chapman J, Miller NJ, Alford B, Bzik DJ, Purmal A. "Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry." Transfusion. 2004 May; 44(5):731-738.
- 3) Fast LD, Semple JW, DiLeone G, Kim M, Freedman J, Chapman J, Purmal A. "Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs." Transfusion. 2004 Feb; 44(2):282-5.
- 4) Zavizion B, Serebryanik D, Serebryanik I, Chapman J, Purmal A. "Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process." Transfusion. 2003 Feb; 43(2):135-42.

D) Riboflavin

- 1) Blajchman MA, Goldman M, Baeza F. "Improving the bacteriological safety of platelet transfusions." Transfus Med Rev. 2004 Jan; 18(1): 11-24.
- 2) Goodrich RP. "The use of riboflavin for the inactivation of pathogens in blood products." Vox Sang. 2000; 78 Suppl 2:211-5. Review.

- 3) Corbin F 3rd. "Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer." Int J Hematol. 2002 Aug; 76 Suppl 2:253-7. Review.

XVII. Derivatives

A) Albumin

- 1) Cochrane. "Injuries Group Albumin Reviewers: Human Albumin Administration in Critically Ill Patients: Systematic Review of Randomized Controlled Trials." Brit Med J. 1998; 317:235-9
- 2) Offringa M. "Excess Mortality after Human Albumin Administration in Critically Ill Patients." Brit Med J. 1998; 317:223-4.
- 3) Berger A. "Why Albumin May Not Work." Brit Med J. 1998; 317:240.
- 4) Wilkes MM, Navickis RJ. "Patient Survival after Human Albumin Administration. A Met-Analysis of Randomized Controlled Trials." Ann Int Med. 2001; 135:149-64.
- 5) Horsey P. "Albumin and Hypovolemia: Is the Cochrane Evidence to be Trusted?" Lancet. 2002; 359:70-2.
- 6) The SAFE Study Investigators*. "A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit." NEJM. 350;22 May 27, 2004.
- 7) Cooper AB, Cohn SM, Zhang HS, Hanna K, Stewart, TE Slutsky AS, the ALBUR Investigators. "Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score." Transfusion. 46; January 2006: 80-89

B) Recombinant Factor VII

- 1) Hedner U, Erhardtsen E: "Potential Role for rFVIIa in Transfusion Medicine." Transfusion. 2002; 42:114-24.
- 2) O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP: "Recombinant FVIIa in the Management of Uncontrolled Hemorrhage." Transfusion. 2003; 43:1711-6.
- 3) Key NS: "Recombinant FVIIa for intractable hemorrhage: More Questions than Answers." Transfusion. 2003; 43:1649-51.
- 4) Midathada MV, Mehta P, Waner M, Fink LM. "Recombinant Factor VIIa in the treatment of bleeding." Am J Clin Path. 2004;121:121-137.

- 5) Barnes C, Blanchette V, Canning P, Carcao M, "Recombinant FVIIa in the Management of Intracerebral Hemorrhage in Severe Thrombocytopenia Unresponsive to Platelet Enhancing Treatment." Transfusion Medicine. 2005, 15, 145–150
- 6) Mittal S, Watson HG. "A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions." British Journal of Haem. 2006:133, pp. 355-363.
- 7) Levy J, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. "Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile." Transfusion. 2006:46:919-933.
- 8) Hoots WK. "Challenges in the Therapeutic Use of a "So-Called" Universal Hemostatic Agent: Recombinant Factor VIIa." Hematology. 2006:426-431.

C) Recombinant Factor VIII

- 1) Van Aken WG. "The Potential Impact of Recombinant Factor VIII on Hemophilia Care and the Demand for Blood and Blood Products." Transfus Med Rev. 1997; 11:6-14.
- 2) Kasper CK, Lusher JM and the AABB Transfusion Practices Committee: "Recent Evolution of Clotting Factor Concentrates for Hemophilia A and B." J Amer Blood Resources Assoc 1993.
- 3) Summer: 44-56. Kasper CK. "Clotting Factor Concentrates in the USA, 2004." Orthopaedic Hospital, Los Angeles, CA.
- 4) Grove GH, Poon M-C, Scarth I. "International Symposium on Recombinant Factor VIII: Report of the Proceedings." Transfus Med Rev. 1992; 6:137-45.

D) Recombinant Factor IX

- 1) Smith KJ: "Factor IX Concentrates: The New Products and their Properties." Transfus Med Rev. 1992;6:124-36.

E) Recombinant Anti-Thrombin III

- 1) Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES. "Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin." Blood. 1998 Jun 15;91(12):4561-71.

F) IVIG

- 1) "Intravenous Immunoglobulin: Prevention and Treatment of Disease". National Institutes of Health, Consensus Development Conference Statement May 21-23, 1990
- 2) Knezevic-Maramica and Kruskall, Margot S. "Intravenous Immune Globulins: an update for clinicians." Transfusion: Volume 43, PP1460-1480, 2003.
- 3) Kazatchkine MD, Kaveri SV: "Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin." NEJM. 2001; 345:747-55.
- 4) Pierce LR, Jain N. "Risks Associated with the Use of Intravenous Immunoglobulin" Transfus Med Rev. 2003;17: 241-51.

XVIII. Donor Reactions

- 1) Newman B, Pichette S, Pichette D, Dzaka E. " Adverse effects in blood donors after whole blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation." Transfusion. 2003; 43:598-603
- 2) Newman BH. " Donor reactions and injuries from whole blood donation." Transfusion Medical Reviews. 1997; 11: 64-75
- 3) Newman B " Vasovagal reaction rates and body weight: findings in high –and low –risk populations." Transfusion. 2003; 43:1084-8
- 4) Shehata N, Kusano R, Hannach B, Humez H. "Reaction Rates in Allogeneic Donors." Transfusion Medicine. 2004, 14, 327–333

XIX. Issues Relevant to Transfusion Medicine

A) Thrombotic Microangiopathies

- 1) Karch H, Friedrich AW, Gerber A, Zimmerhackl LB, Schmidt MA, Bielaszewska M. "New Aspects in the Pathogenesis of Enteropathic Hemolytic Uremic Syndrome." Seminars in Thrombosis and Hemostasis. 2006:32,2, pp. 105-112.
- 2) Galbusera M, Noris M, Remuzzi G. "Thrombotic Thrombocytopenic Purpura—Then and Now." Seminars in Thrombosis and Hemostasis. 2006:32,2, pp. 81-89.
- 3) George JN. "Thrombotic Thrombocytopenic Purpura." NEJM. 2006:354, pp. 1927-35.
- 4) Desch K, Motto D. "ADAMTS13 and VWF: not just for TTP anymore?" Blood. 2005:106, pp 4024.
- 5) Karpman D, Papadopoulou D, Nilsson K, Sjogren A, Mikailsson C, Lethagen, S. "Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome." Blood. 2001:97, pp. 3100-3108.
- 6) Franchini M. "Thrombotic microangiopathies: An update." Hematology. 2006:11(3): 139-146.

B) Hemochromatosis

- 1) Leitman SF, Browning JN, Yau YY, Mason G, et. Al. "Hemochromatosis subjects as allogeneic blood donors: a prospective study." Transfusion. 2003:43, pp 1538-1544.
- 2) Barton JC, Grindon AJ, Barton NH, Bertoli LF. "Hemochromatosis probands as blood donors." Transfusion. 1999:39, pp 578-585.
- 3) Sacher RA. "Hemochromatosis and blood donors: a perspective." Transfusion. 1999:39, pp 551-554
- 4) Conry-Cantilena C. "Phlebotomy, Blood Donation, and Hereditary Hemochromatosis." Trans Med Reviews. 2001:15, pp 136-143.
- 5) Worwood M. "Inherited iron loading: genetic testing in diagnosis and management." Blood Reviews. 2005:19, pp 69-88.
- 6) Brissot P, Guyader D, Loreal O, et al. "Clinical aspects of hemochromatosis." Trans Sci. 2000:23, pp 193-200.
- 7) Brissot P, de Bels F. "Current Approaches to the Management of Hemochromatosis." Hematology. 2006:36-41.

- 8) McDonnell SM, Preston BL, Jewell SA, et al. "A Survey of 2,851 Patients with Hemochromatosis: Symptoms and Response to Treatment." Am Journal of Medicine. 1999:106, pp 619-624.
- 9) Heeney MM, Andrews NC. "Iron homeostasis and inherited iron overload disorders: an overview." Hematol Oncol Clin N Am. 2004:18, pp 1379-1403.
- 10) Beutler E, Hoffbrand AV, Cook J. "Iron Deficiency and Overload." Hematology. 2003: pp 40-61.
- 11) Schwartz SO, Blumenthal SA. "Exogenous Hemochromatosis resulting from blood transfusion." Blood. 1948:3, pp 617-640.
- 12) Kushner JP, Porter JP, Olivieri NF. "Secondary Iron Overload." Hematology. 2001: pp 41-61.
- 13) U.S. Preventive Services Task Force. "Screening for Hemochromatosis: Recommendation Statement." Ann Intern Med. 2006:145(5):204-208.
- 14) Ganz T. "Hepcidin and Its Role in Regulating Systemic Iron Metabolism." Hematology. 2006:29-35
- 15) Atanasiu V, Manolescu B, Stoian I. "Hepcidin – central regulator of iron metabolism." Eu J Haem. 2006:78:1-10.

C) Thrombophilia

- 1) Robertson B, Greaves M. "Antiphospholipid syndrome: An evolving story." Blood Reviews. 2006:20:201-212.
- 2) Simioni P, Tomene D, Spiezia L, Tognin G, Rossetto V, et al. "Inherited Thrombophilia and Venous Thromboembolism." Semin Thromb Hemost. 2006:32:700-708.

D) ADAMTS13

- 1) Kentouche K, Zintl F, Angerhaus D, Fuchs D, Hermann J, et al. "von Willebrand Factor-Cleaving Protease (ADAMTS13) in the Course of Stem-Cell Transplantation." Seminars in Thrombosis and Hemostasis. 2006:32,2, pp. 98-104.
- 2) Rock G, Yousef H, Neurath D, Lu M. "ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma." Trans and Apher Sci. 2006:35:235-238.

E) Photopheresis

- 1) Heshmati F, Andreu G. "Extracorporeal photochemotherapy: a historical perspective." Trans and Apheresis Sci. 2003:28, pp. 25-34.
- 2) Peritt, D. "Potential Mechanisms of Photopheresis in Hematopoietic Stem Cell Transplantation." Biol of Blood and Marrow Trans. 2006:12, pp. 7-12.
- 3) Schooneman, F. "Extracorporeal photopheresis technical aspects." Trans and Apheresis Sci. 2003:28, pp.51-61.
- 4) Knobler R, Jantschitsch C. "Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma." Trans and Apheresis Sci. 2003:28, pp. 81-89.
- 5) Demierre MF, Kim YH, Zackheim HS. "Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma." Hematol Oncol Clin N Am. 2003:17, pp. 1485-1507.
- 6) Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. "Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease: Does It Work?" Biol of Blood and Marrow Trans. 2006:12, pp. 37-40.
- 7) Zic JA, Miller JL, Stricklin GP, King Jr LE. "The North American Experience with Photopheresis." Therapeutic Apheresis. 1999:3, pp. 50-62.
- 8) Greinix Ht, Socie G, Baciagalup A, Holler E, Edinger MG, et al. "Assessing the potential role of photopheresis in hematopoietic stem cell transplant." Bone Marrow Trans. 2006:38:265-273.
- 9) Messina C, Locatelli F, Lanino E, Udeerzo C, Zacchello, G, et al. "Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation." Brit Jour Haemat. 2003:122:118-127.

F) Heparin-Induced Thrombocytopenia

- 1) Laber DA, Martin ME. "Etiology of thrombocytopenia in all patients treated with heparin products." Eur J Haematol. 2005:75, pp 101-105.
- 2) Keeling D, Davidson S, Watson H. "The management of heparin-induced thrombocytopenia." British Society for Haematology Guideline. June 18, 2006.
- 3) Kodityal S, Manhas AH, Udden M, Rice L. "Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures." Eur J Haematol. 2003:71:109-113.

- 4) Warkentin TE, Sheppard JI. "Testing for Heparin-Induced Thrombocytopenia Antibodies." Trans Med Rev. 2006:20(4): 259-272.
- 5) Warkentin TE. "Think of HIT." Hematology. 2006:408-414;

G) Sickle Cell Disease

- 1) Lottenberg R, Hassell KL. "An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease." Hematology. 2005:pp 58-65.
- 2) Danielson CFM. "The Role of Red Blood Cell Exchange in the Treatment and Prevention of the Complications of Sickle Cell Disease." Ther Aph. 2002:6, pp 24-31.
- 3) Swerdlow PS. "Red Cell Exchange in Sickle Cell Disease." Hematology. 2006:48-53.
- 4) Platt OS. "Prevention and Management of Stroke in Sickle Cell Anemia." Hematology. 2006:54-57.

H) Anemia in the Elderly

- 1) Eisenstaedt R, Penninx BW, Woodman RC. "Anemia in the elderly: Current understanding and emerging concepts." Blood Reviews. 2006:20:213-226.

I) Blood Usage and Cardiac Surgery

- 1) Alghamdi AA, Davis A, Brister S, Corey P, Logan A. "Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs." Transfusion. 2006:46:1120-1129.
- 2) Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. "Effects of Cardiac Surgery on Hemostasis." Trans Med Reviews. 2006:20(3):230-241.
- 3) Slight RD, Bappu NJ, Nzewi OC, Lee RJ, McClelland BL, Mankad PS. "Factors predicting loss and gain of red cell volume in cardiac surgery patients." Trans Med. 2006:16:169-175.
- 4) Van de Watering L, Lorinser J, Versteegh M, Westendorp R, Brand A. "Effects of storage time of red blood cell transfusion on the prognosis of coronary artery bypass graft patients." Transfusion. 2006:46:1712-1718.

- 5) Tinmouth AT. "The value of a clinical prediction rule for allogeneic transfusion in cardiac surgery." Transfusion. 2006;46:1072-1074.
- 6) Ferguson TB. "Aprotinin – Are There Lessons Learned?" JAMA. 2007;297;5:527-529.
- 7) Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, et al. "Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery." JAMA. 2007;297;5:471-479.

J) C Reactive Protein and Cardiac Disease

- 1) Yaron G, Brill A, Dashevsky O, Yosef-Levi IM, Grad E, Danenberg HD, Varon D. "C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway to atherothrombosis." Br Jour Haem. 2006;134:426-431.

K) LDL Apheresis

- 1) Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. "LDL-Apheresis Reduces P-Selectin, CRP and Fibrinogen – Possible Important Implications for Improving Atherosclerosis." Ther Aph and Dial. 2006;10(3):219-223.
- 2) Hereshcovici T, Schechner V, Orlin J, Harell D, Beigel Y. "Effect of Different LDL-Apheresis Methods on Parameters Involved in Atherosclerosis." J Clin Apher. 2004;19:90-97.
- 3) Sachais BS, Katz J, Ross J, Rader DJ. "Long-Term Effects of LDL Apheresis in Patients With Severe Hypercholesterolemia." J Clin Apher. 2005;20:252-255.
- 4) Kobayashi S, Moriya H, Maesato K, Okamoto K, Ohtake T. "LDL-Apheresis Improves Peripheral Arterial Occlusive Disease With an Implication for Anti-Inflammatory Effects." J Clin Apher. 2005;20:239-243.

L) von Willebrands Disease

- 1) Koutts J. "A Short History of Diagnostic Tests for von Willebrand Disease: In Memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988)." Semin Thromb and Hemost. 2006:32(5):445-455.
- 2) Favaloro EJ, Michiels JJ. "Laboratory Issues in the Identification and Diagnosis of von Willebrand Disease. On the 80th Anniversary of Erik von Willebrand's Original Publication." Semin Thromb Hemost. 2006:32:443-444.
- 3) Favaloro EJ. "Laboratory Identification of von willebrand Disease: Technical and Scientific Perspectives." Semin Thromb Hemost. 2006:32:456-471.
- 4) Kouides PA. "Aspects of the Laboratory Identification of von Willebrand Disease in Women." Semin Thromb Hemost. 2006:32:480-484.
- 5) Mazurier C. "Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willbrand disease." Semin Thromb Hemost. 2006:32:529-536.
- 6) National Institutes of Health. "The Diagnosis, Evaluation, and Management of von Willebrand Disease (draft)." May 30, 2006.
- 7) Franchini M. "Advances in the diagnosis and management of von Willebrand disease." Hematology. 2006:11(4):219-225.

M) Myelodysplasia

- 1) Catenacci DVT, Schiller GJ. "Myelodysplastic syndromes: A comprehensive review." Blood Reviews. 2005:19:301-319.
- 2) Fenaux P, Kelaidi C. "Treatment of the 5q-Syndrome." Hematology. 2006:192-198.
- 3) Schiffer CA. "Clinical Issues in the Management of Patients with Myelodysplasia." Hematology. 2006:205-210.
- 4) De Witte T, Oosterveld M, Muus P. "Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome." Blood Reviews. 2007:21:49-59.

N) Hemovigilance

- 1) Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, et al. "Serious Hazards of Transfusion: A Decade of Hemovigilance in the UK." Trans Med Rev. 2006:20(4): 273-282.
- 2) Dzik W. "New technology for transfusion safety." Br J Haematology. 2006:136:181-190.

O) Porphyria

- 1) Sassa, S. "Modern diagnosis and management of the porphyrias." Br Jour Haem. 2006:135:281-292.

XVIII. Symposium on Transplantation

- 1) Cooley S, June CH, Schoenberger SP, Miller JS. "Adoptive Therapy with T Cell/NK Cells." Biol Blood and Marr Transplant. 2006:13:33-42.
- 2) Blaise D, Bregni M. "Allogeneic Stem Cell Transplantation for Solid Tumors: Which Way Forward?" Biol Blood and Marr Transplant. 2007:13:73-75.
- 3) Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. "Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment." Biol Blood and Marr Transplant. 2007:13:34-72.
- 4) Jones Rj, Matsui W. "Cancer Stem Cells: From Bench to Bedside." Biol Blood and Marr Transplant. 2007:13:47-52.
- 5) Young JW, Merad M, Hart DNJ. "Dendritic Cells in Transplantation and Immune-Based Therapies." Biol Blood and Marr Transplant. 2007:13:23-32.
- 6) Filipovich AH, Bleasing J, Goldman F. "Emerging Targets of Hematopoietic Cell Transplantation (HCT): Genetic Disorders of Hematopoiesis and Immunity." Biol Blood and Marr Transplant. 2007:13:58-63.
- 7) Cudihy AR, Crooks GM. "Endothelial Biology and the Bone Marrow." Biol Blood and Marr Transplant. 2007:13:43-46.
- 8) Chao N. "Regulatory T Cells: Historical Perspective." Biol Blood and Marr Transplant. 2007:13:11.

- 9) Heslop H. "Letter from the Editor: The 2007 Educational Supplement on Hemopoietic Cell Transplantation." Biol Blood and Marr Transplant. 2007:13:1.
- 10) Gress RE, Komanduri KV, Einsele H, Cooper LJM. "Lymphoid Reconstruction and Vaccines." Biol Blood and Marr Transplant. 2007:13:17-22.
- 11) Champlin R. "Graft Biology: Marrow Versus Peripheral Blood Versus Cord Blood." Biol Blood and Marr Transplant. 2007:13:76.
- 12) Girdt S, Simmonds M, Smith R. "Measure of Morbidity: Functional Assessment and Cytokines." Biol Blood and Marr Transplant. 2007:13:98-102.
- 13) Horwitz EM, Andreef M, Frassoni F. "Mesenchymal Stromal Cells." Biol Blood and Marr Transplant. 2007:13:53-57.
- 14) Barrett J. "New Technologies to Visualize T Cell Function: A Picture Tells a Thousand Words." Biol Blood and Marr Transplant. 2007:13:110.
- 15) Confer DL, Miller JP. "Optimal Donor Selection: Beyond HLA.": Biol Blood and Marr Transplant. 2007:13:83-86.
- 16) Negrin RS, Hou, JZ. "Promise and Challenges of Human Regulatory T Cells in the Clinic." Biol Blood and Marr Transplant. 2007:13:12-16.
- 17) Sandmaier BM, Mackinnon S, Childs RW. "Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives." Biol Blood and Marr Transplant. 2007:13:87-97.
- 18) Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. "Transplantation's Greatest Challenges: Advances in Chronic Graft-versus-Host Disease." Biol Blood and Marr Transplant. 2007:13:2-10.
- 19) Nolan G. "Visualizing Inside the Cell." Biol Blood and Marr Transplant. 2007:13:120-123.
- 20) Kupfer A. "Visualizing the Immune Synapse." Biol Blood and Marr Transplant. 2007:13:115-119.
- 21) Huang A. "Watching Immune Cells in Action." Biol Blood and Marr Transplant. 2007:13:111-114.
- 22) Barker JN. "Who Should Get Cord Blood Transplants?" Biol Blood and Marr Transplant. 2007:13:78-82.

XIX. Rheopheresis

- 1) Pulido JS, Winter J. "Rheopheresis for Macular Degeneration: The Data Is Not There Yet to Justify It." J Clin Apher. 2005:20:168.
- 2) Pulido J, Snader D, Winter JL, Klingel R. "Clinical Outcomes and Mechanism of Action for Rheopheresis Treatment of Age-Related Macular Degeneration (AMD)." J Clin Apher. 2005:20:185-194.

XX. Miscellaneous

- 1) Chant C, Wilson G, Friedrich JO. "Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study." Critical Care. 2006;10(5):1-9.
- 2) Franchini M, Veneri D, Lippi G. "Inherited factor XI deficiency: A concise review." Hematology. 2006;11(5/6):307-309.